FDA-like AI safety approval process delays NVIDIA's next-gen GPU by Q…

Market overview

If the Trump administration implements an FDA-like approval process for advanced AI models, NVIDIA's next-generation GPUs—expected to power cutting-edge AI systems—will face mandatory safety reviews. This could delay commercial releases by at least one quarter.

tech_stocks prediction market

Implied probability (Yes)

60%

Source: user-generated

More tech_stocks markets

• S&P 500 Energy Sector outperforms broader market by 5% in June 2026 — 55% Yes
• Broadcom stock rises 15% within 6 months due to AI partnerships — 70% Yes
• GPT-5.5-Cyber surpasses Mythos in simulated cyberattack completion rate by 2027 — 68% Yes
• Nvidia’s stock will rise above $200 by 2026-12-31 — 75% Yes
• US Army accelerates AI deployment in Africa by 2027 — 68% Yes
• OpenAI to release v1.0 AGI system by December 2026 — 65% Yes
• Micron stock rises 20% by end of Q2 2026 — 65% Yes
• Netflix introduces interoperable Clips-like feed with Prime Video by Q1 2027 — 70% Yes

Browse all tech_stocks markets →